Skip to Content Skip to Search

Compassionate use (Expanded access)

Two employees talking in an office

Our purpose at GSK is to improve the quality of patient's lives by helping to prevent and treat disease with vaccines, specialty and general medicines.

We recognise that there may be instances when it is appropriate for Healthcare Professionals to seek an unapproved medicine or vaccine for treatment use for a patient where no satisfactory alternatives exist. Our policy and programmes may provide an option for providers and patients faced with these challenges.

Compassionate use policy

Please read our policy on compassionate use here

Healthcare Professional requests for compassionate use

Our policy on compassionate use can be accessed above.

If you are a Healthcare Professional who would like to request compassionate use of a GSK investigational medicine for a patient, please use the GSK Compassionate Use Request Portal.  You will need to create a profile before you can submit your request.

In order to handle your enquiry, we are required to record and maintain the personal information that you have provided to us.  This may include your name and contact details. This personal information will be processed solely for the purpose of dealing with your enquiry.  More detailed information on the processing of your personal information is available from our Privacy Notice.

Patient requests for compassionate use

Our compassionate use policy

If you are a patient and would like to make a request for compassionate use of a GSK investigational medicine, please contact your Healthcare Professional.

Importation of Unlicensed Medicines programme

The Importation of Unlicensed Medicines programme may provide a mechanism for a physician to treat a patient with a GSK medication that has been approved in a major market but is not yet approved in their country for the same indication.

Patient eligibility includes:

  • Serious or life-threatening disease
  • No alternative treatments available
  • Inability to participate in a clinical trial

For oncology, please contact

For any other request please connect with your local GSK entity via Worldwide | GSK

NP-GBL-NA-WCNT-210001 / July 2021